Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 1;46(2):e143-e146.
doi: 10.1097/MPH.0000000000002812. Epub 2024 Jan 17.

Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review

Binni Kunvarjee  1 , Molly Siver  1 , Sherry Mathew  1 , Samantha Steiger  1 , Yeon Joo Lee  2 , Barbara Spitzer  3
Affiliations

Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review

Binni Kunvarjee et al. J Pediatr Hematol Oncol. .

Abstract

Isavuconazonium sulfate (ISA) is a triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis in adults. This single-center, retrospective review of pediatric oncology and stem cell transplant patients receiving ISA for prophylaxis (n=20) or treatment (n=6) of invasive fungal disease (IFD) aims to characterize real-world clinical efficacy and toxicity of ISA in patients <18 years of age. Of 20 patients receiving ISA for prophylaxis, three patients had presumed breakthrough IFD (1 proven, 2 probable/possible). No adverse effects were attributed to ISA use or led to the discontinuation of therapy.

PubMed Disclaimer

Conflict of interest statement

Y.J.L. has served as an investigator for Astellas, Karius, AiCuris, and Scynexis and has received research grant support from Merck & Co Inc. M.S. and B.S. are currently employed/are affiliated with Hackensack University Medical Center; S.M is currently employed/is affiliated with Pfizer; S.S. is currently employed/is affiliated with Takeda Pharmaceuticals. The remaining authors declare no conflict of interest.

References

    1. Alexander S, Pole JD, Gibson P et al. Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncol 2015; 16: e604–610. DOI: 10.1016/S1470-2045(15)00197-7 - DOI - PubMed
    1. Lehrnbecher T, Fisher BT, Phillips B et al. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. J Clin Oncol 2020; 38: 3205–3216. DOI: 10.1200/JCO.20.00158 - DOI - PMC - PubMed
    1. Marty FM, Perfect JR, Cornely OA et al. 824An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis. Open Forum Infectious Diseases 2014; 1: S235–S236. DOI: 10.1093/ofid/ofu052.532 - DOI
    1. Maertens JA, Raad II, Marr KA et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016; 387: 760–769. DOI: 10.1016/S0140-6736(15)01159-9 - DOI - PubMed
    1. Donnelly JP, Chen SC, Kauffman CA et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71: 1367–1376. DOI: 10.1093/cid/ciz1008 - DOI - PMC - PubMed

Publication types